CTN-0102-XR: Rural Expansion of Medication Treatment for Opioid Use Disorder: Randomized Controlled Pilot Trial of Extended-Release Buprenorphine vs. Sublingual Buprenorphine-naloxone in Rural Settings

This two-year pilot study will explore the feasibility, acceptability, and effectiveness of the most recent formulation of injectable extended-release buprenorphine (XR-BUP) for the treatment of opioid use disorder  in rural settings, as compared to sublingual buprenorphine-naloxone (SL-BUP).

If you are interested in learning more about this study, please email RuralMOUD@mednet.ucla.edu.

CTN-0131: Office-based Methadone Versus Buprenorphine to Address Retention in Medication for Opioid Use Disorder Treatment – A Randomized Pragmatic Hybrid Effectiveness/Implementation Trial

This study will address the problem of sub-optimal retention in office-based buprenorphine (BUP) treatment for opioid use disorder and will expand access to methadone in settings other than opioid treatment programs. Clinicians currently have two options for patients not optimally benefitting from office-based BUP. They can attempt to enhance BUP-related services or refer the patient to an OTP for methadone. This study will evaluate a new option: office-based methadone prescribing (under special arrangements) with off-site methadone dispensing. Study investigators will conduct a hybrid effectiveness/implementation trial to compare: (1) office-based methadone where the current office-based BUP prescriber manages a switch to and continuation of methadone in partnership with a local methadone dispensing facility versus (2) enhanced BUP where the office-based BUP provider continues BUP treatment while providing enhanced behavioral treatment and/or implementing strategies to address adherence if indicated. Investigators will use mixed methods and an implementation science framework to identify implementation barriers and facilitators at the patient, provider, and health-system levels for office-based methadone.

If you are interested in learning more about this study, please email Sherry Larkins, PhD (larkins@g.ucla.edu).

CTN-0139: Collaborative Care for Polysubstance Use in Primary Care Settings (Co-Care) Trial

* Please note, this is not a comprehensive list of all CTN studies that are recruiting sites. Refer to the NIDA CTN Protocols webpage for more information study statuses

The CTN-0139 study is a cluster-randomized controlled trial testing the effectiveness of the Co-Care collaborative care intervention vs. enhanced usual care (EUC) for reducing polysubstance use and improving health and functioning in adult primary care patients. This nation-wide study will select five sites, each having 1-3 clinics, for participation. The trial will enroll and randomize primary care providers (PCPs); patients with polysubstance use will be subsequently enrolled and will receive the Co-Care intervention or EUC according to the assignment of their PCP. Research staff will screen and enroll patients and PCPs, and patients participate for 12 months. Research assistants follow up with patients and collect data off-site (by telephone, internet).

If you are interested in learning more about this study, please email Sherry Larkins, PhD (larkins@g.ucla.edu).